Targeted Cancer Drugs Damage the Gut in Ways Clinicians Often Miss
Precision Oncology's Side-Effect Problem
Targeted cancer therapies have reshaped treatment for colorectal, gastric, liver, and other GI cancers over the past two decades. By binding to specific molecular targets rather than broadly poisoning dividing cells, drugs like tyrosine kinase inhibitors, antibody-drug conjugates, and CAR-T cell therapies offer more selective tumor killing with theoretically reduced collateral damage. In practice, however, the gastrointestinal tract -- which contains some of the most rapidly dividing cells in the body -- often ends up in the crossfire.
A review published in Oncoscience (Volume 13, February 2026) by researchers at the University of Missouri-Columbia examines how these three drug classes injure the gut, what those injuries look like under a microscope, and how clinicians can avoid misinterpreting them. The authors argue that gastrointestinal toxicity from targeted cancer therapy is both more common and more varied than current clinical practice accounts for.
Three Drug Classes, Three Injury Profiles
Tyrosine kinase inhibitors (TKIs) block enzymatic signals that cancer cells depend on for growth. Some of those same signals regulate blood vessel formation in the intestinal wall. When TKIs suppress vascular growth in the gut, the result can range from mild diarrhea and abdominal cramping to bleeding and, in rare cases, bowel perforation -- a potentially life-threatening complication that can be confused with a ruptured diverticulum or perforated ulcer.
Antibody-drug conjugates (ADCs) pair a targeted antibody with a cytotoxic payload. The antibody directs the drug to cancer cells, but some delivery is non-specific, exposing normal intestinal lining cells to the cytotoxin. This can cause nausea, vomiting, mucositis, and colitis. On biopsy, the tissue damage may look similar to medication-induced colitis from other causes or from immune checkpoint inhibitors, making drug attribution difficult without a complete medication history.
CAR-T cell therapies involve engineering a patient's own T cells to recognize and attack tumor antigens, then infusing them back. The dramatic immune activation this generates can spill over into GI tissue, causing widespread inflammatory injury indistinguishable on initial presentation from infectious colitis or inflammatory bowel disease. Pathologists looking at biopsy material see cell death, ulceration, or non-specific inflammation -- findings that can be entirely misattributed to more familiar conditions.
The Diagnostic Gaps
Misdiagnosis is not rare. A patient presenting with severe diarrhea, abdominal pain, or bloody stool after cancer treatment may be evaluated by a gastroenterologist who does not have full knowledge of all the agents the patient has received, particularly when treatment was conducted at a different institution. Without knowing that the patient received an ADC three weeks earlier, the pathologist reviewing biopsy material has no reason to look for drug-related injury rather than infection or primary inflammatory bowel disease.
The authors call for tighter collaboration between oncologists, gastroenterologists, and pathologists. They also note that the FDA Adverse Event Reporting System (FAERS) contains valuable data on the frequency and pattern of GI complications associated with specific drugs, and that integrating these databases with clinical and pathological findings could strengthen drug safety monitoring.
The review is based on literature synthesis, clinical trial reports, FDA drug labels, and safety databases rather than a prospective patient study. Research gaps identified by the authors include real-world histopathology correlation studies, investigation of gut microbiome effects on toxicity severity, and validation of biomarkers that might predict which patients will develop serious GI complications from specific drug classes.